Fangsheng Pharmaceutical(SH:603998) Sou Hu Cai Jing·2025-12-21 13:56Core Viewpoint - The company Fangsheng Pharmaceutical (603998) held a product launch and investor reception event on December 21, discussing recent operations, research and development, and new product plans, highlighting the inclusion of its innovative traditional Chinese medicine "Yangxue Qufeng Zhitong Granules" in the 2025 National Medical Insurance Directory through recent negotiations [1] Group 1: Strategic Plans - The company plans to increase investment in innovative traditional Chinese medicine, aiming to accelerate the progress of its research pipeline over the next three years [1] - The company aims to create a product matrix with multiple products achieving annual sales of 300 to 500 million yuan [1] - For the newly included "Yangxue Qufeng Zhitong Granules," the company has set a market target for 2026 to cover over 500 public medical institutions and strives for its sales revenue to exceed that of its previous innovative product "Xuanqi Jiangu Pian" in its first year [1] Group 2: Research and Development - The company currently has a research pipeline for innovative traditional Chinese medicine covering multiple departments, with several projects such as "Yiqi Xiaoliu Granules" and "Ziying Granules" having received clinical trial approval [1] - The chemical drug research project "Indobufen Tablets" has obtained a drug registration certificate [1] Group 3: Financial Performance - In the first three quarters, the company achieved a net profit attributable to shareholders of 268 million yuan, representing a year-on-year increase of 17.60% [1] - The industrial hemp business of the company's wholly-owned subsidiary, Yunnan Fuya Biotechnology Co., Ltd., generated nearly 20 million yuan in revenue in the first three quarters of 2025, showing significant year-on-year growth, with expectations for annual revenue to exceed 30 million yuan for the first time [1]